Evergreening of patents is a corporate strategy where pharmaceutical companies seek secondary patents on minor modifications of known drugs to extend their statutory twenty-year market monopoly. In India, Section 3(d) of the Patents Act 1970 strictly prevents this practice by requiring proof of significantly enhanced therapeutic efficacy, protecting patient access to affordable generic medicines.
Understanding Evergreening in the Pharmaceutical Sector
In the pharmaceutical industry, developing a new chemical entity involves substantial capital expenditure and extensive clinical trials. In return for disclosing the invention, patent legislation awards the inventor an exclusive statutory monopoly for twenty years. Under ideal circumstances, the expiry of this twenty-year term allows generic manufacturers to produce affordable bioequivalent versions, drastically lowering the cost of treatment for patients.
However, multinational pharmaceutical corporations frequently adopt incremental modification strategies known as evergreening. Rather than discovering novel therapeutic molecules, companies introduce minor structural changes, such as new salt forms, polymorphs, isomers, dosage forms, or combinations of known substances. By filing successive patent applications for these variations shortly before the primary patent expires, corporations attempt to stretch their commercial exclusivity across decades. This practice restricts market competition, inflates healthcare expenditures, and directly conflicts with patient welfare.
Section 3(d) of the Indian Patents Act and the Novartis Benchmark
When India amended its Patents Act in 2005 to comply with product patent requirements, parliament introduced strong statutory safeguards to prevent frivolous patenting. Section 3(d) provides that the mere discovery of a new form of a known substance which does not result in the enhancement of the known efficacy of that substance is not an invention.
The legal boundary of Section 3(d) was authoritatively settled by the Supreme Court of India in the landmark decision of Novartis AG vs. Union of India (2013). Novartis had sought a patent for the beta crystalline form of Imatinib Mesylate, marketed as Glivec for treating chronic myeloid leukemia. While Novartis claimed improved bioavailability and thermodynamic stability, the Supreme Court held that enhanced physical properties do not equate to enhanced therapeutic efficacy. The court affirmed that in the case of pharmaceutical substances, efficacy strictly denotes curative effect or therapeutic benefit.
The interpretation of statutory standards in specialized fields reflects principles familiar in broader constitutional law principles regarding the right to health under Article 21 of the Constitution, ensuring that statutory monopolies do not extinguish affordable life-saving care.
TRIPS Agreement Flexibilities and the Public Health Mandate
The Trade-Related Aspects of Intellectual Property Rights (TRIPS) Agreement establishes baseline international standards for intellectual property protection. Nevertheless, the WTO Doha Declaration on the TRIPS Agreement and Public Health (2001) affirmed that the treaty can and should be interpreted and implemented in a manner supportive of WTO members' right to protect public health and promote access to medicines for all.
India has utilized these flexibilities by defining rigorous patentability criteria that discourage evergreen filings. While foreign trade bodies periodically raise concerns regarding Indian standards, India's framework remains fully compliant with WTO TRIPS Agreement standards while preventing monopolies on routine derivative compounds.
National Seminar at Chanakya National Law University: Patents vs. Patients
To examine these evolving legal tensions, Chanakya National Law University (CNLU), Patna, organized a UGC-sponsored National Seminar titled "Ever Greening of Patents (Patents V/S Patients)". The academic gathering brought together legal scholars, judicial officers, practitioners, and researchers to dissect the complex intersections of intellectual property and public health.
The seminar addressed key sub-themes that continue to define pharmaceutical patent disputes in India:
- Evergreening Tactics: Technical analysis of patent prosecution strategies involving crystalline forms, formulations, and prodrugs.
- Impact of TRIPS: Evaluating international compliance, trade disputes, and sovereign policy flexibilities.
- Healthcare and Pharmaceutical Access: The socio-economic role of Indian generic manufacturers in domestic and global health supply chains.
- Access vs. Protection: Striking an equitable balance between rewarding true inventive steps and ensuring patient affordability.
- Judicial Activism in Patent Law: How Indian courts interpret statutory thresholds to prevent patent abuse and anticompetitive market practices.
Submissions presented at the seminar followed rigorous academic standards, utilizing Bluebook citation format and structured empirical analysis. Methodical analysis of statutory boundaries and case records mirrors the evidentiary precision observed in Supreme Court of India civil precedents, where clear statutory interpretation governs competing commercial interests.
Balancing Innovation and Healthcare Equity
The debate surrounding patents versus patients highlights the fundamental purpose of patent systems: encouraging genuine scientific progress without compromising public welfare. India's patent architecture, anchored by Section 3(d), pre-grant and post-grant opposition mechanisms, and compulsory licensing provisions, demonstrates how national legislation can prevent evergreening while encouraging authentic technological advancement.